JP2010524942A - プロリルヒドロキシラーゼを阻害するキノロン及びアザキノロン - Google Patents

プロリルヒドロキシラーゼを阻害するキノロン及びアザキノロン Download PDF

Info

Publication number
JP2010524942A
JP2010524942A JP2010504084A JP2010504084A JP2010524942A JP 2010524942 A JP2010524942 A JP 2010524942A JP 2010504084 A JP2010504084 A JP 2010504084A JP 2010504084 A JP2010504084 A JP 2010504084A JP 2010524942 A JP2010524942 A JP 2010524942A
Authority
JP
Japan
Prior art keywords
methyl
oxo
hydroxy
oxobutyric acid
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2010504084A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010524942A5 (OSRAM
Inventor
アレン，ジエニフアー・アール
ブーリ，ローラント
ブライアン，マリアン・シー
ツアオ，クオ−チヤン
ネイラ，スサナ・セー
リード，アンソニー・ビー
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2010524942A publication Critical patent/JP2010524942A/ja
Publication of JP2010524942A5 publication Critical patent/JP2010524942A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2010504084A 2007-04-18 2008-04-16 プロリルヒドロキシラーゼを阻害するキノロン及びアザキノロン Ceased JP2010524942A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92528507P 2007-04-18 2007-04-18
US92774807P 2007-05-04 2007-05-04
PCT/US2008/004965 WO2008130600A2 (en) 2007-04-18 2008-04-16 Quinolones and azaquinolones that inhibit prolyl hydroxylase

Publications (2)

Publication Number Publication Date
JP2010524942A true JP2010524942A (ja) 2010-07-22
JP2010524942A5 JP2010524942A5 (OSRAM) 2011-06-02

Family

ID=39766967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010504084A Ceased JP2010524942A (ja) 2007-04-18 2008-04-16 プロリルヒドロキシラーゼを阻害するキノロン及びアザキノロン

Country Status (7)

Country Link
US (2) US8048894B2 (OSRAM)
EP (1) EP2142509B1 (OSRAM)
JP (1) JP2010524942A (OSRAM)
AU (1) AU2008241483B2 (OSRAM)
CA (1) CA2683956C (OSRAM)
ES (1) ES2442847T3 (OSRAM)
WO (1) WO2008130600A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013184893A (ja) * 2012-03-06 2013-09-19 Tokyo Univ Of Agriculture & Technology トリフルオロメチルピリジノン化合物およびその製造方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635715B2 (en) * 2006-12-18 2009-12-22 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
CA2683956C (en) * 2007-04-18 2012-12-18 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
WO2009089547A1 (en) 2008-01-11 2009-07-16 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
PT2294066E (pt) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
WO2010022240A1 (en) 2008-08-20 2010-02-25 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
CN102272117B (zh) 2008-11-14 2015-06-17 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
TWI485150B (zh) * 2009-07-17 2015-05-21 Japan Tobacco Inc 三唑并吡啶化合物及其作為脯胺醯基羥化酶抑制劑或紅血球生成素生產誘導劑之作用
JP5676769B2 (ja) 2010-10-14 2015-02-25 イムナール アクティエボラーグ Ａｈｒ活性化因子としての１，２‐ジヒドロ‐４‐ヒドロキシ‐２‐オキソ‐キノリン‐３‐カルボキシアニリド
WO2012106472A1 (en) 2011-02-02 2012-08-09 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
EP2776023B1 (en) 2011-10-25 2016-03-09 Janssen Pharmaceutica, N.V. Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
US20140256767A1 (en) * 2011-10-31 2014-09-11 The Broad Institute, Inc. Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
WO2014022728A1 (en) 2012-08-02 2014-02-06 Endo Pharmaceuticals, Inc Substituted 5 - (quinazolin - 2 - yl) pyrimidin- 2 -amine derivatives useful as pi3k/mtor inhibitors for the treatment of cancer
FR2994184B1 (fr) * 2012-08-02 2017-12-08 Biomerieux Sa Procedes de fonctionalisation et reactifs utilises dans de tels procedes utilisant un anhydride aza-isatoique ou un de ses derives, molecules biologiques ainsi traitees et kits
AP2015008502A0 (en) * 2012-12-24 2015-06-30 Cadila Healthcare Ltd Novel quinolone derivatives
CN105384687B (zh) 2014-09-02 2018-05-01 广东东阳光药业有限公司 喹啉酮类化合物及其在药物中应用
CN114302882A (zh) * 2019-07-19 2022-04-08 威佛（国际）股份公司 用于治疗输血依赖型β-地中海贫血（tdt）的膜铁转运蛋白抑制剂
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
PE20230609A1 (es) 2020-05-04 2023-04-13 Amgen Inc Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso
EP4146345A2 (en) 2020-05-05 2023-03-15 Teon Therapeutics, Inc. Cannabinoid receptor type 2 (cb2) modulators and uses thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US79726A (en) * 1868-07-07 Hbney bfllard
JPS5245474B2 (OSRAM) 1972-04-19 1977-11-16
JPS5417754B2 (OSRAM) 1972-12-15 1979-07-02
CA1022544A (en) 1972-12-21 1977-12-13 Yukiyasu Murakami Process of preparing a heterocyclic acyl group-substituted cephalosporin derivative
JPS587637B2 (ja) 1973-12-27 1983-02-10 住友化学工業株式会社 シンキペニシリンノ セイホウ
AT328085B (de) 1974-04-23 1976-03-10 Sumitomo Chemical Co Verfahren zur herstellung neuer penicilline
US4215123A (en) 1979-05-07 1980-07-29 American Home Products Corporation Antisecretory 4-oxy-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
US4468394A (en) 1981-04-02 1984-08-28 Eisai Co., Ltd. Cephalosporin compounds
US4374138A (en) 1981-11-13 1983-02-15 Warner-Lambert Company Antibacterial amide compounds, compositions, and methods of use
US4404201A (en) 1981-11-13 1983-09-13 Warner-Lambert Company Cephalosporins
US4382089A (en) 1982-03-02 1983-05-03 Warner-Lambert Company Antibacterial amide compounds, compositions thereof and methods of using them
US4710473A (en) 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
US5037826A (en) 1986-10-15 1991-08-06 Schering Corporation 1-substituted naphthyridine and pyridopyrazine derivatives
SU1735288A1 (ru) 1990-03-05 1992-05-23 Харьковский государственный фармацевтический институт Способ получени N-R-замещенных амидов 4-гидроксихинолон-2 карбоновой -3-кислоты
JP2988739B2 (ja) 1990-04-16 1999-12-13 協和醗酵工業株式会社 １，８−ナフチリジン−２−オン誘導体
JPH0493592A (ja) 1990-08-09 1992-03-26 Nissan Motor Co Ltd 回転蓄熱式熱交換器
IL100917A0 (en) 1991-02-16 1992-11-15 Fisons Plc Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them
US5155115A (en) 1991-03-12 1992-10-13 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
DE4138820A1 (de) 1991-11-26 1993-05-27 Basf Ag Chinolin-3-carbonsaeureamide, deren herstellung und verwendung
AU668694B2 (en) 1991-12-19 1996-05-16 Sanofi-Synthelabo Saccharin derivative proteolytic enzyme inhibitors
DE4227747A1 (de) 1992-08-21 1994-02-24 Basf Ag Heteroaromatisch kondensierte Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung
US5502035A (en) 1993-08-06 1996-03-26 Tap Holdings Inc. N-terminus modified analogs of LHRH
CA2138929A1 (en) 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
JPH07224040A (ja) 1994-02-07 1995-08-22 Fujisawa Pharmaceut Co Ltd キノリン誘導体
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2260499A1 (en) 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Pharmaceutical compositions for the treatment of ischemic brain damage
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
GB9911047D0 (en) 1999-05-12 1999-07-14 Isis Innovation Assay method and means
AU2001252671A1 (en) 2000-05-12 2001-11-20 Kyorin Pharmaceutical Co. Ltd. Pyridobenzodiazine derivatives and processes for the preparation thereof
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
AU2002303145A1 (en) 2001-03-23 2002-10-08 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
ES2414706T3 (es) 2001-12-06 2013-07-22 Fibrogen, Inc. Métodos para aumentar la eritropoyetina endógena
EP2045242A1 (en) 2002-08-13 2009-04-08 Shionogi&Co., Ltd. Heterocyclic compounds having inhibitory activity against HIV integrase
US7019141B2 (en) 2002-10-21 2006-03-28 Irm Llc Quinolones with anti-HIV activity
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
WO2004103974A1 (ja) 2003-05-23 2004-12-02 Japan Tobacco Inc. 置換２－オキソキノリン化合物およびその医薬用途
WO2004104000A1 (ja) 2003-05-23 2004-12-02 Japan Tobacco Inc. トリサイクリック縮合環化合物およびその医薬用途
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2004108681A1 (en) 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
JP4057972B2 (ja) * 2003-07-25 2008-03-05 富士通株式会社 半導体装置の製造方法
WO2005011696A1 (en) 2003-08-01 2005-02-10 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
AU2004268941A1 (en) 2003-08-22 2005-03-10 Avanir Pharmaceuticals Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
US7378414B2 (en) 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
JP2007510649A (ja) 2003-11-04 2007-04-26 メルク　エンド　カムパニー　インコーポレーテッド 置換ナフチリジノン誘導体
JP4859676B2 (ja) 2004-02-11 2012-01-25 スミスクライン ビーチャム コーポレーション Ｈｉｖインテグラーゼ阻害剤
BRPI0511267A (pt) 2004-05-17 2007-11-27 Tibotec Pharm Ltd 1,5-diidropirido[3,2-b]indol-2-onas 4-substituìdas
US20100130737A1 (en) 2005-02-18 2010-05-27 Takeda Pharmaceutical Company Limited Regulating Agent of GPR34 Receptor Function
ATE513833T1 (de) 2005-03-02 2011-07-15 Fibrogen Inc Thienopyridinverbindungen und verfahren zu ihrer verwendung
AR055319A1 (es) 2005-03-17 2007-08-15 Wyeth Corp Derivados de isoquinoleina, composiciones farmaceuticas y usos
EP1893186A2 (en) 2005-06-06 2008-03-05 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
DE602006014843D1 (de) 2005-06-15 2010-07-22 Fibrogen Inc Verwendung von hif 1alfa modulatoren zur behandlung von krebs
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
US7728130B2 (en) 2005-12-09 2010-06-01 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
WO2007097929A1 (en) 2006-02-16 2007-08-30 Fibrogen, Inc. Compounds and methods for treatment of stroke
US7625927B2 (en) 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
TW200808793A (en) 2006-03-07 2008-02-16 Smithkline Beecham Corp Prolyl hydroxylase inhibitors
US20090176825A1 (en) 2006-05-16 2009-07-09 Fitch Duke M Prolyl hydroxylase inhibitors
TWI394747B (zh) 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
JP4876041B2 (ja) 2006-08-30 2012-02-15 株式会社リコー 画像形成装置
WO2008040002A2 (en) 2006-09-28 2008-04-03 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for hif modulating compounds
ES2393326T3 (es) 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
US7635715B2 (en) 2006-12-18 2009-12-22 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
CA2683956C (en) 2007-04-18 2012-12-18 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
AU2008248165B2 (en) 2007-05-04 2011-12-08 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
WO2008137060A1 (en) * 2007-05-04 2008-11-13 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013184893A (ja) * 2012-03-06 2013-09-19 Tokyo Univ Of Agriculture & Technology トリフルオロメチルピリジノン化合物およびその製造方法

Also Published As

Publication number Publication date
US8048894B2 (en) 2011-11-01
EP2142509A2 (en) 2010-01-13
US20090156605A1 (en) 2009-06-18
AU2008241483B2 (en) 2011-03-24
US8349868B2 (en) 2013-01-08
US20110224248A1 (en) 2011-09-15
CA2683956C (en) 2012-12-18
WO2008130600A3 (en) 2009-02-19
AU2008241483A1 (en) 2008-10-30
EP2142509B1 (en) 2013-12-04
WO2008130600A2 (en) 2008-10-30
CA2683956A1 (en) 2008-10-30
ES2442847T3 (es) 2014-02-13

Similar Documents

Publication Publication Date Title
US8048894B2 (en) Quinolones and azaquinolones that inhibit prolyl hydroxylase
US8030346B2 (en) Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
US8097620B2 (en) Diazaquinolones that inhibit prolyl hydroxylase activity
US8048892B2 (en) Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
US7569726B2 (en) Indanone derivatives that inhibit prolyl hydroxylase
US8017626B2 (en) Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110413

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20130307

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130703

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140425

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141111

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20150324